ACM
NTLA icon

Aster Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Aster Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.74K Buy
+386
New +$4.92K ﹤0.01% 735
2025
Q2 		– Sell
-5,859
Closed -$59.1K – 1407
2025
Q1 		$59.1K Buy
5,859
+5,527
+1,665% +$55.8K 0.01% 775
2024
Q4 		$3.87K Buy
+332
New +$5.18K ﹤0.01% 896

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aster Capital Management's NTLA Position: Q1 2026 in Review

Aster Capital Management opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 386 shares worth $2.74K. The stake represents ﹤0.01% of the portfolio and ranks #735 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in NTLA as recently as Q1 2025.

Aster Capital Management first reported a position in NTLA in Q4 2024 and has held it in 3 quarters since. The position peaked at $59.1K in Q1 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Aster Capital Management held 386 shares of Intellia Therapeutics worth $2.74K as of Q1 2026.
  • Intellia Therapeutics was a new Aster Capital Management position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q1 2026, its #735 holding.
  • Aster Capital Management first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Aster Capital Management's Intellia Therapeutics position peaked at $59.1K in Q1 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.